Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes

James A de Lemos, David A. Morrow

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Management of patients with acute coronary syndromes (ACS) is becoming more complex as the array of treatment options available to patients and physicians continues to expand. Cardiac biomarkers play an important role in risk stratification in ACS, and results of cardiac biomarker tests can be used to help guide choices between alternative therapies. In addition to biomarkers of myocyte necrosis, markers of neurohormonal activation, such as B-type natriuretic peptide (BNP), provide important prognostic information in ACS. In the future, multimarker strategies that incorporate panels of cardiac biomarkers are likely to be used for risk stratification and for pathophysiology-guided treatment in patients with ACS.

Original languageEnglish (US)
JournalReviews in Cardiovascular Medicine
Volume4
Issue numberSUPPL. 4
StatePublished - 2003

Fingerprint

Natriuretic Peptides
Acute Coronary Syndrome
Necrosis
Biomarkers
Brain Natriuretic Peptide
Complementary Therapies
Muscle Cells
Physicians
Therapeutics

Keywords

  • Acute coronary syndromes
  • B-type natriuretic peptide
  • C-reactive protein
  • Cardiac troponins
  • Creatine kinase
  • Myoglobin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. / de Lemos, James A; Morrow, David A.

In: Reviews in Cardiovascular Medicine, Vol. 4, No. SUPPL. 4, 2003.

Research output: Contribution to journalArticle

@article{73762d9ce457410cabdb1b2664e3e9a2,
title = "Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes",
abstract = "Management of patients with acute coronary syndromes (ACS) is becoming more complex as the array of treatment options available to patients and physicians continues to expand. Cardiac biomarkers play an important role in risk stratification in ACS, and results of cardiac biomarker tests can be used to help guide choices between alternative therapies. In addition to biomarkers of myocyte necrosis, markers of neurohormonal activation, such as B-type natriuretic peptide (BNP), provide important prognostic information in ACS. In the future, multimarker strategies that incorporate panels of cardiac biomarkers are likely to be used for risk stratification and for pathophysiology-guided treatment in patients with ACS.",
keywords = "Acute coronary syndromes, B-type natriuretic peptide, C-reactive protein, Cardiac troponins, Creatine kinase, Myoglobin",
author = "{de Lemos}, {James A} and Morrow, {David A.}",
year = "2003",
language = "English (US)",
volume = "4",
journal = "Reviews in Cardiovascular Medicine",
issn = "1530-6550",
publisher = "MedReviews LLC",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes

AU - de Lemos, James A

AU - Morrow, David A.

PY - 2003

Y1 - 2003

N2 - Management of patients with acute coronary syndromes (ACS) is becoming more complex as the array of treatment options available to patients and physicians continues to expand. Cardiac biomarkers play an important role in risk stratification in ACS, and results of cardiac biomarker tests can be used to help guide choices between alternative therapies. In addition to biomarkers of myocyte necrosis, markers of neurohormonal activation, such as B-type natriuretic peptide (BNP), provide important prognostic information in ACS. In the future, multimarker strategies that incorporate panels of cardiac biomarkers are likely to be used for risk stratification and for pathophysiology-guided treatment in patients with ACS.

AB - Management of patients with acute coronary syndromes (ACS) is becoming more complex as the array of treatment options available to patients and physicians continues to expand. Cardiac biomarkers play an important role in risk stratification in ACS, and results of cardiac biomarker tests can be used to help guide choices between alternative therapies. In addition to biomarkers of myocyte necrosis, markers of neurohormonal activation, such as B-type natriuretic peptide (BNP), provide important prognostic information in ACS. In the future, multimarker strategies that incorporate panels of cardiac biomarkers are likely to be used for risk stratification and for pathophysiology-guided treatment in patients with ACS.

KW - Acute coronary syndromes

KW - B-type natriuretic peptide

KW - C-reactive protein

KW - Cardiac troponins

KW - Creatine kinase

KW - Myoglobin

UR - http://www.scopus.com/inward/record.url?scp=0141891427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141891427&partnerID=8YFLogxK

M3 - Article

VL - 4

JO - Reviews in Cardiovascular Medicine

JF - Reviews in Cardiovascular Medicine

SN - 1530-6550

IS - SUPPL. 4

ER -